Dupixent Sales Surge 38% to €5.15B, Sanofi Raises 2026 Outlook
REGN sits 29% above its 52-week low of $541.
Summary
Sanofi's Q2 results show Dupixent sales soaring 38% to €5.15 billion, well above the €4.48 billion consensus, driving a full-year sales outlook raise to 10% growth. Regeneron shares in Dupixent profits, making this a direct positive read-through. The beat was broad: Sanofi's total revenue of €11.60 billion and business operating income of €3.29 billion both exceeded estimates. New CEO Belen Garijo is also reshaping the pipeline, scrapping three experimental drugs, which may refocus resources on higher-potential assets. This follows Regeneron's own strong pipeline news in May, including positive melanoma data and a gene therapy filing acceptance. The Dupixent strength reinforces Regeneron's near-term revenue trajectory and could lift sentiment ahead of its own Q2 report.
At the time of this announcement, REGN was trading at $700.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $72.9B. The 52-week trading range was $541.00 to $821.11. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.